Safety and efficacy of NVX-CoV2373 Covid-19 vaccine

BACKGROUND Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that contains the full-length spike glycoprotein of the prototype strain plus Matrix-M adjuvant, showed that the v...

Full description

Bibliographic Details
Main Authors:	Heath, PT, Galiza, EP, Baxter, DN, Boffito, M, Browne, D, Burns, F, Chadwick, DR, Clark, R, Cosgrove, C, Galloway, J, Goodman, AL, Heer, A, Higham, A, Iyengar, S, Jamal, A, Jeanes, C, Kalra, PA, Kyriakidou, C, McAuley, DF, Meyrick, A, Minassian, AM, Minton, J, Moore, P, Munsoor, I, Nicholls, H, Osanlou, O, Packham, J, Pretswell, CH, San Francisco Ramos, A, Saralaya, D, Sheridan, RP, Smith, R, Soiza, RL, Swift, PA, Thomson, EC, Turner, J, Viljoen, ME, Albert, G, Cho, I, Dubovsky, F, Glenn, G, Rivers, J, Robertson, A, Smith, K, Toback, S
Other Authors:	2019nCoV-302 Study Group
Format:	Journal article
Language:	English
Published:	Massachusetts Medical Society 2021

Safety and efficacy of NVX-CoV2373 Covid-19 vaccine

Similar Items